Avid Bioservices Inc (CDMO)

[bimerkjaere]

Agreed, to be consider for breakthrough therapy or an accelerated approval, I would presume you would need stronger data than what the final 2nd-line results will provide. Perhaps I am wrong, but we likely lost our opportunity of a near-term approval after the discrepancies were found. A fantastic pancreatic result could change this, but this trial seems too small for the FDA to be convinced (IMO).